FDA Outlines Path Forward for Verve’s Lead Candidate, VERVE-101

FDA Outlines Path Forward for Verve’s Lead Candidate, VERVE-101

Submitted by admin on December 5, 2022 - 10:55pm
Source: 
BioSpace
News Tags: 
Verve Therapeutics
VERVE-101
FDA
heterozygous familial hypercholesterolemia
Headline: 
FDA Outlines Path Forward for Verve’s Lead Candidate, VERVE-101
snippet: 

The FDA appears to be taking an ultra-cautious approach with base editing technology. Monday, Verve Therapeutics revealed that the FDA has officially requested several buckets of additional safety information to lift the hold on its lead candidate, VERVE-101.

Do Not Allow Advertisers to Use My Personal information